Krystal Biotech's decision date for experimental treatment drug receives 3-month delay from FDA

Krystal's candidate to treat dystrophic epidermolysis bullosa candidate, which is sometimes referred to as "butterfly child" due to the fragile-like conditions that become of the skin as a result of the disease, has seen a delay.